Scientific Publications

KEYNOTE-B79 Phase 1b trial to evaluate the allogeneic CAR T-cells CYAD-101 and pembrolizumab in refractory metastatic colorectal cancer patients

IMMUNICY-1: Targeting BCMA with CYAD-211 to Establish Proof Of Concept of An shRNA-based Allogeneic CAR T-cell Therapy Platform

Armoring NKG2D-based CAR T cells with IL-18 improves in vitro and in vivo anti-tumor activity

Evolving Multiplexed shRNA to generate tailored CAR T cell therapy

A Phase 1b KEYNOTE-B79 trial evaluating non-gene edited allogeneic CAR T-cells, CYAD-101, post FOLFOX preconditioning, followed by pembrolizumab, in refractory metastatic colorectal cancer patients

Objective response at low dose in the first-in-human IMMUNICY-1 trial evaluating non-gene edited allogeneic CYAD-211 anti-BCMA CAR T product in relapsed or refractory multiple myeloma

ASCO GI: Updated Data from the alloSHRINK Phase 1 First-in-Human Study Evaluating CYAD-101, an Innovative Non-Gene-Edited Allogeneic CAR-T, in Metastatic Colorectal Cancer

ASH: Results from the Phase I Clinical Studies Evaluating CYAD-01, a first-generation NKG2D CAR T-cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

ASH: Clinical Development of a Non-Gene-Edited Allogeneic BCMA-Targeting CAR T-cell Product in Relapsed or Refractory Multiple Myeloma

ASH: First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating CYAD-02, an Optimized Non-Gene-Edited Engineered NKG2D CAR T-cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

ASCO: Single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T-cells

ASCO: CYAD-101, an innovative non-gene edited allogeneic CAR-T for solid tumor cancer therapy

Results from the completed dose escalation of the hematological arm of the phase I THINK study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients

Interim results from the phase I DEPLETHINK trial evaluating the infusion of a NKG2D CAR T-cell therapy post a non-myeloablative conditioning in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients

Next generation NKG2D-based CAR-T cells (CYAD-02): Co-expression of a single shRNA targeting MICA and MICB improves cell persistence and anti-tumor efficacy in vivo

Results from the completed dose-escalation of the ALLOSHRINK phase I study evaluating the allogeneic NKG2D-based CAR T-cell therapy CYAD-101 in metastatic colorectal cancer patients

Results from the completed dose-escalation phase I SHRINK study evaluating the autologous NKG2D-based CAR T-cell therapy CYAD-01 in metastatic colorectal cancer patients

Effect of chemotherapy on cellular kinetics of NKG2D-based CAR T-cells in metastatic colorectal cancer patients

The targeted knockdown of CD3ζ by shRNA as a platform to develop allogeneic CAR T cell therapy

The targeted knockdown of CD3ζ by shRNA as a platform to develop allogeneic CAR T cell therapy

Understanding the expression profile of NKG2D ligands on T cells: Implications for CAR T cell therapy

Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR T therapy in metastatic colorectal cancer

DEVELOPMENT OF A NEXT GENERATION ALLOGENEIC CAR-T CELL PLATFORM WITHOUT GENE EDITING

Updated results from Phase I trials assessing a NKG2D CAR T-cell approach in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients

MODELING NKG2D-BASED CAR-T CELL THERAPY IN ANIMALS WITH ACUTE MYELOID LEUKEMIA

NKG2D as a chimeric antigen receptor – DAP10 provides optimal co-stimulation for NKG2D-based CARs

NKG2D as a chimeric antigen receptor – DAP10 provides optimal co-stimulation for NKG2D-based CARs

Interim results from the phase I DEPLETHINK trial evaluating the infusion of a NKG2D CAR T-cell therapy post a non-myeloablative conditioning in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients

Results from the completed dose escalation of the hematological arm of the phase I THINK study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia

Pooling signaling and costimulatory domains in a flexible CARpool design

Functional screening of different anti-B7H6 CAR designs

Differential effects of target ligands upon NKG2D CAR T cell activation

Overcoming target‐driven fratricide for CAR‐T cell therapy

CYAD-101: an allogeneic NKG2D CAR T cell therapy using a TCR inhibitory molecule

Generating Allogeneic CAR T cells without Gene Editing

Endogenous DAP10 provides optimal co‐stimulation for NKG2D‐based CARs

Uncovering the phenotype, functional and homing properties of NKG2D CAR T cells

The co-expression of a single shRNA targeting MICA and MICB with a NKG2D CAR generates CAR-T cells resistant to target driven fratricide and improves CAR T cell persistence in vivo

Results and perspectives from Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic solid tumors

Tackling fratricide to manufacture clinical grade NKG2D‐CAR T cells for cancer therapy

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Metastatic Colorectal Cancer

The high expression of NKG2D ligands on tumor and non‐tumor cells and a lack of surface expression on healthy tissues provide a strong rationale to support NKG2D‐based therapeutic approaches for cancer.

Expression of a TIM peptide reduces alloreactivity of T cells facilitating an allogeneic NKG2D Chimeric Antigen Receptor T cell therapy approach

Overcoming target-driven fratricide for CAR-T cell therapy

Functional screening of an anti-B7H6 specific chimeric antigen receptor (CAR)

The THINK clinical trial: Preliminary evidence of clinical activity of NKG2D Chimeric Antigen Receptor T cell therapy (CYAD-01) in acute myeloid leukemia

NKG2D as a chimeric antigen receptor – DAP10 provides optimal co-stimulation for NKG2D-based CARs

A Phase 1 study assessing the safety and clinical activity of multiple doses of an NKG2D-based CAR-T therapy, CYAD-01, administered concurrently with neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer

A Phase 1 study assessing the safety and clinical activity of multiple hepatic transarterial administrations of an NKG2D-based CAR-T therapy, CYAD-01, in patients with unresectable liver metastases from colorectal cancer

A Phase I Global Trial Targeting Multiple Solid and Hematologic Malignancies through a NKG2D receptor-based CAR-T Immunotherapy

A NKG2D-based CAR-T therapy in a Multinational Phase 1 Dose Escalation and Expansion Study Targeting Multiple Solid and Hematologic Tumor Types

Safety Data from a First-in-Human Phase I Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma

Safety Data from a First-in-Human Phase I Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma

A First-in-Human Phase I Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma